Business context and reporting period
The supplied filing is Salarius Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2020—not a filing identified as Decoy Therapeutics Inc. Investors should verify the issuer and filing match their intended company. Salarius is a clinical-stage cancer drug developer; its lead candidate is seclidemstat (SP-2577), an LSD1 inhibitor. It has no products approved for sale and no product-sales revenue.
Financial results and liquidity
| Metric | Q3 2020 | Q3 2019 | Nine months 2020 | Nine months 2019 |
|---|---|---|---|---|
| Grant revenue | $1.38 million | $0.87 million | $3.75 million | $2.43 million |
| Research and development expense | $1.80 million | $1.14 million | $4.89 million | $2.68 million |
| General and administrative expense | $1.33 million | $3.49 million | $4.89 million | $5.95 million |
| Net loss | $1.72 million | $2.63 million | $5.58 million | $5.05 million |
| Basic and diluted loss per share | $0.10 | $0.73 | $0.40 | $1.68 |
At September 30, cash and cash equivalents were $9.56 million, grants receivable $3.21 million, working capital $11.46 million, total assets $23.06 million, total liabilities $2.46 million, and stockholders’ equity $20.61 million. Current liabilities included a $761,096 note payable. The filing reports $8.94 million of cash used in operating activities during the first nine months, offset by $14.76 million of financing cash inflows; cash increased $5.82 million. The financing included approximately $14.8 million net proceeds from February and August public offerings and approximately $0.6 million from warrant exercises. No operating margin is presented; the company reported operating losses.
Material changes versus prior comparable periods
Q3 grant revenue rose 58% year over year, while R&D expense rose 58%, primarily due to drug manufacturing preparations and higher personnel and consulting costs, partly offset by lower clinical-trial spending. Q3 G&A fell 62%, largely because significant 2019 public-company transition legal and professional costs did not recur. The Q3 net loss narrowed by $0.91 million. For the nine-month period, revenue rose 55%, R&D expense increased 82% with expanded trial-site and manufacturing activity, and G&A declined 18%; net loss increased 11%. Changes in warrant fair value contributed noncash gains of $45,103 in Q3 and $265,538 for the nine months.
Outlook, risks, contingencies, and unusual items
Management stated that cash on hand and expected CPRIT grant funding were expected to support operations into the second half of 2021, but also disclosed substantial doubt about the company’s ability to continue as a going concern and that available resources were insufficient to fund planned operations for the next 12 months from the financial statements. It expects to need substantial additional capital and may pursue equity, debt, or collaborations; financing may not be available on acceptable terms and could dilute shareholders or constrain operations.
The CPRIT grant had an extended contract end date of May 31, 2021. The company reported $3.21 million of grant receivable and no CPRIT funding received during the nine months. Approximately $2.6 million of the remaining grant was associated with a prostate cancer study the company elected not to pursue and is no longer available. The grant is subject to conditions, including matching funds and potential repayment in certain circumstances.
Management reported minimal COVID-19 disruption to date but warned of possible trial-enrollment, supplier, manufacturing, operational, and financing disruptions. The Ewing sarcoma trial was expanded to include selected Ewing-related sarcomas. Early patient observations were mixed: target lesions decreased after six months, but progression of non-target lesions resulted in an overall progressive-disease classification at eight weeks. On October 5, 2020, Nasdaq notified the company that its 30-day average closing price was below $1.00; the company had 180 calendar days to regain compliance. Management reported disclosure controls were effective and no material legal proceedings were pending.
Important facts for investors to verify
- Confirm that this Salarius Pharmaceuticals filing, rather than Decoy Therapeutics, is the intended issuer.
- Assess the going-concern disclosure, projected cash runway, monthly cash use, and ability to raise additional capital.
- Verify the timing, eligibility, matching requirements, and collectability of CPRIT funds, including the reported grant receivable.
- Track clinical-trial enrollment, safety and efficacy data, manufacturing needs, and the implications of the mixed early patient observation.
- Check subsequent Nasdaq bid-price compliance and potential effects of further financing or dilution.